Preview Mode Links will not work in preview mode

Keep up to date on mental health news, free CME, and live events. Subscribe to our podcast and join our email list!

Oct 28, 2021

In this episode, Dr. Andrew Cutler interviews Dr. Roger McIntyre on best practices for using adjunctive treatment for major depressive disorder.

Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click https://nei.global/POD21-MDD

Learning Objectives: After completing this educational activity, you should be better able to:

  • Discuss earlier identification of partial response to anti-depressants and advantages to implementing augmentation strategies sooner to improve treatment outcomes
  • Increase awareness about evidence-based adjunctive treatments that are FDA-approved for depression
  • Examine the pharmacological profiles of approved adjunctive atypical antipsychotic treatments in terms of how they relate to therapeutic benefits and adverse reactions

Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

NEI designates this online live activity for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME/CE Credit Types. The following are being offered for this activity:

  • Nursing (ANCC): 1.0 contact hour
  • Pharmacy (ACPE): 1.0 application-based contact hour
  • Physician (ACCME): 1.0 AMA PRA Category 1 Credit
  • Physician Assistant (AAPA): 1.0 Category 1 CME credit
  • Psychology (APA): 1.0 CE credit
  • Social Work (ASWB-ACE): 1.0 ACE CE credit
  • Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for 1.0 AMA PRA Category 1 Credit

Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.

Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Potential conflicts of interest are identified and resolved prior to the activity being presented.

Interviewer

Andrew J. Cutler, MD

Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY

Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA

Consultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva

Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris

 Interviewee

Roger S. McIntyre, MD, FRCPC

Professor, Departments of Psychiatry and of Pharmacology; Head, Mood Disorders Psychopharmacology Unit, University Health Network; University of Toronto, Toronto, ON, Canada

Grant/Research: CIHR/GACD/National Natural Science Foundation of China

Consultant/Advisor: AbbVie, Bausch Health, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Neurocrine, Novo Nordisk, Otsuka, Pfizer, Purdue, Sunovion, Takeda

Speakers Bureau: AbbVie, Bausch Health, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Neurocrine, Novo Nordisk, Otsuka, Pfizer, Purdue, Sunovion, Takeda

 Pre-Interview Author

Sabrina K. Bradbury-Segal, PhD

Medical Writer, Neuroscience Education Institute, Carlsbad, CA

No financial relationships to disclose.

The Planning Committee and Peer Reviewer have no financial relationships to disclose.

Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.

Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found here: https://nei.global/culture

Support: This activity is supported by an unrestricted educational grant from Otsuka America Pharmaceutical, Inc. and Lundbeck.

Released: October 21, 2021          CE credit expires: October 21, 2024